COGT is the ticker symbol for Cogent Biosciences, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks COGT with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is COGT a good stock to buy?

COGT is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/COGT.

Where does 13F Pro source COGT data?

All Cogent Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cogent Biosciences, Inc. files with the SEC under CIK 1622229. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Cogent Biosciences, Inc.(COGT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Cogent Biosciences, Inc. (COGT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. COGT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Cogent Biosciences, Inc. reports net income of $-96.4M, free cash flow of $-77.6M. Top institutional holders of COGT by reported 13-F value include FMR, BlackRock, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. COGT trades on the Nasdaq exchange and files with the SEC under CIK 1622229. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COGT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cogent Biosciences, Inc. directly from SEC EDGAR.

Net Income

$-96.4M

Free Cash Flow

$-77.6M

COGT key financials by period

Cogent Biosciences, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2020	10-K	$7.9M	$-74.8M	—
FY 2019	10-K	$22.5M	$-31.8M	-143.0%
FY 2018	10-K	$9.7M	$-34.5M	—
FY 2017	10-K	$8.4M	$-25.5M	—

Institutions holding COGT

Institutional investors reporting a position in Cogent Biosciences, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
FMR	25,681,174	$993.9M	2026-06-30
BlackRock	17,352,646	$671.5M	2026-06-30
VANGUARD PORTFOLIO MANAGEMENT	8,072,411	$312.4M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	7,412,330	$286.9M	2026-06-30
STATE STREET	6,964,919	$269.5M	2026-06-30
Jupiter Topco	6,624,848	$256.4M	2026-06-30
Fairmount Funds Management	5,503,418	$213.0M	2026-06-30
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	5,006,104	$193.7M	2026-06-30
TCG Crossover Management	4,854,436	$187.9M	2026-06-30
PRICE T ROWE ASSOCIATES	4,652,727	$180.1M	2026-06-30

SEC EDGAR: CIK 1622229 →

Cogent Biosciences, Inc.

COGT

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.